^
    27d
    A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=66, Active, not recruiting, Akesobio Australia Pty Ltd | Recruiting --> Active, not recruiting | N=143 --> 66 | Trial primary completion date: Jan 2025 --> Oct 2024
    Enrollment closed • Enrollment change • Trial primary completion date • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • lancastotug (AK127)
    5ms
    A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC). (clinicaltrials.gov)
    P1/2, N=280, Not yet recruiting, Akeso
    New P1/2 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Kaitanni (cadonilimab) • Yidafan (ivonescimab) • lancastotug (AK127)
    9ms
    A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=143, Recruiting, Akesobio Australia Pty Ltd | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • lancastotug (AK127)
    over1year
    A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Not yet recruiting, Akeso
    New P1/2 trial
    |
    Yidafan (ivonescimab) • lancastotug (AK127)
    over1year
    A Study of AK127 Combined With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1a/1b, N=205, Not yet recruiting, Akeso
    New P1 trial • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • lancastotug (AK127)